

1 **Exploring *WNT2* Polymorphisms in Comitant Strabismus: A Genetic Association Study**

2 Zainab Zehra,¹ Christopher S. von Bartheld,² Andrea B. Agarwal,² Hans Vasquez-Gross,³ Sorath

3 Noorani Siddiqui,⁴ Maleeha Azam,^{1,§} Raheel Qamar^{5,6,§}

4

5 ¹Translational Genomics Laboratory, Department of Biosciences, COMSATS University

6 Islamabad, Pakistan;

7 ²Department of Physiology and Cell Biology, University of Nevada, Reno School of Medicine,

8 Reno, NV, USA;

9 ³Nevada Bioinformatics Center, RRID: SCR_017802, University of Nevada, Reno;

10 ⁴Al-Shifa Eye Trust Hospital, Rawalpindi, Pakistan;

11 ⁵Pakistan Academy of Sciences, Islamabad, Pakistan;

12 ⁶Science and Technology Sector, ICESCO, Rabat, Kingdom of Morocco

13

14

15 Shared correspondence

16 § Address for correspondence

17 **Raheel Qamar**, Head of Science and Technology Sector, ICESCO, Rabat, Morocco. Phone:

18 (212)-(537 56 60 52); Email: raheelqamar@hotmail.com

19 **Maleeha Azam**, Translational Genomics Laboratory, Department of Biosciences, COMSATS

20 University Islamabad, Pakistan, Tarlai Kalan, Park Road, Islamabad-45600, Pakistan. Phone:

21 (92)-(51)-9235033; Fax: (92)-(51)-9247008; Email: malihazam@gmail.com

22 **Abstract**

23 Background: Strabismus is a complex oculomotor condition characterized by a misalignment of
24 the visual axis. The genetics of strabismus are poorly defined although a few candidate genes
25 have been identified, among which is the *WNT2* gene. Our study was designed to assess the
26 association of single nucleotide polymorphisms (SNPs) of *WNT2* in Pakistani strabismus
27 patients.

28 Methods: A total of six SNPs, three intronic and three in the 3' untranslated region, were
29 screened in the current study. Logistic regression was performed using a dominant, recessive and
30 additive model to determine the association of SNPs with strabismus and its clinical subtypes:
31 esotropia and exotropia. Furthermore, haplotype analysis was performed.

32 Results: Regression analysis revealed an association of rs2896218, rs3779550, rs2285544 and
33 rs4730775 with strabismus under the dominant model. When analyzed separately, rs2896218 and
34 rs2285544 were found to be associated with both esotropia and exotropia, while rs4730775 was
35 significantly associated only with exotropia under the dominant model. Based on clinical
36 parameters, rs2896218, rs2285544 and rs4730775 were also found to be associated with the
37 group of strabismus patients who were diagnosed at birth, but not in the group of patients who
38 were diagnosed later in life. Haplotype analysis revealed that the haplotype A T T
39 (corresponding to rs2896218, rs3779550 and rs2285544) was significantly more prevalent in the
40 strabismus group.

41 Conclusion: Overall, the results of the present study suggests an association of *WNT2*
42 polymorphisms with strabismus and its subtypes in the Pakistani population, though further
43 studies are needed to elucidate their role in strabismus etiology.

44 **What is already known on this topic**

- 45 • Strabismus is a common oculomotor condition with a genetic component.
46 • *WNT2* has been identified as a candidate gene for comitant strabismus.

47 **What this study adds**

- 48 • Two *WNT2* polymorphisms not previously reported have been found to be associated
49 with strabismus.
50 • There are genetic variations between clinical subtypes of strabismus (esotropia and
51 exotropia).
52 • *WNT2* polymorphisms are associated with age at the time of diagnosis and family history.
53 • Combinations of different alleles (haplotypes) are associated with the disease.

54 **How this study might affect research, practice or policy**

- 55 • Our study adds to the limited genetic data for strabismus and suggests further studies on
56 the role of *WNT2* in strabismus causation.

57 Introduction

58 Strabismus is a common ocular disorder with a worldwide prevalence of 2-3%. The prevalence
59 of horizontal subtypes of strabismus, esotropia and exotropia, vary in different parts of the world
60 and can be influenced by several risk factors such as ethnicity,¹ seasonality of birth,² gestational
61 age and birth weight, paternal age, and family history.³

62 Comitant strabismus (CS), where the degree of misalignment remains constant regardless of the
63 direction of gaze, accounts for more than 95% of all strabismus cases. Despite being fairly
64 common, the mechanisms underlying its onset are poorly understood. Genetics and a positive
65 family history have been implicated in playing a significant role in the disease. Recent studies
66 have aimed to identify genetic variants responsible for disease causation. In 2018, a genome
67 wide association study (GWAS) by Shabaan et al., (2018)⁴ identified a significant association of
68 rs2244352 in intron 1 of the *WRB* with non-accommodative esotropia in an American population
69 of European ancestry. Two studies identified *LRP2* and *FOXG1* as potential candidate genes for
70 strabismus,^{5,6} while another study suggested *MGST2* and *WNT2* as potential candidate genes for
71 strabismus in a Japanese population.⁷

72 *WNT2* is a member of the *WNT* family of genes, which encode several secreted signaling
73 proteins. These genes play an important role in early development such as neural development
74 and patterning during embryogenesis,⁸ including early development of ocular tissues.⁹ WNTs are
75 also involved in embryonic muscle development by regulating the activity of myogenic
76 regulatory factors.¹⁰ *WNT2* plays a role in the activation of the canonical WNT signalling
77 pathway by acting as a ligand for Frizzled receptors.¹¹ *WNT2* can also initiate differentiation of
78 embryonic stem cells via a non-canonical WNT signalling pathway¹² and may also be involved
79 in the development of embryonic brains.¹³

80 *WNT2* is located on chromosome 7 (7q31.2), which has previously been identified as a
81 susceptibility locus for CS.¹⁴ The same group later identified *WNT2* as a candidate gene for CS at
82 this locus. Being an important signalling molecule, together with being a candidate gene for CS,
83 we therefore explored potential roles of the *WNT2* gene by screening its previously reported
84 polymorphisms in a cohort of strabismus patients. The aim of the present study was to
85 investigate whether single nucleotide polymorphisms (SNPs) in *WNT2* are associated with
86 strabismus or its clinical subtypes.

87 **Methods**

88 **Ethical Review and Cohort Recruitment**

89 Our project was approved by the Ethics Review Board, Department of Biosciences, COMSATS
90 University Islamabad (CUI-Reg/Notif-452/20/526) and conforms to the tenets of the Declaration
91 of Helsinki. All participants and/or accompanying guardians were briefed about the purpose of
92 the study and written consent was obtained prior to sample collection.

93 Strabismus patients were recruited from the Al-Shifa Trust Eye Hospital, Rawalpindi after
94 diagnosis by an experienced ophthalmologist, which included cover test, prism cover test and
95 Hirschberg test. All participants were briefed about the study before their clinical data were
96 collected. Complete data of all the participants was not available as they or their accompanying
97 guardians had limited information such as, about other strabismus cases in the family or age of
98 the patient at first diagnosis.

99 **Inclusion/Exclusion Criteria**

100 Patients diagnosed with CS were included in the study regardless of age, gender, or ethnic
101 background. Patients having a history of any other ocular disorder, ocular surgery, trauma or
102 injury to the eye, or any neurological condition were excluded from the study. Patients suffering
103 from phoria, vertical strabismus, paralytic strabismus, and amblyopia-induced strabismus were
104 also excluded. Age-matched healthy controls were recruited from local schools and universities
105 including students and staff.

106 **Sample Collection and DNA Extraction**

107 A total of 5mL blood was collected from each individual in EDTA tubes and stored at 4°C prior
108 to use. Genomic DNA was isolated from the whole blood using the organic phenol/chloroform
109 method as described by Sambrook and Russel (2001)¹⁵ with minor modifications.

110 **Gene and SNP Selection**

111 Previous genetic linkage studies have identified the 7q31.2 gene locus¹⁴ and *WNT2* gene⁷ as a
112 candidate for strabismus. In our study, we screened a total of six *WNT2* polymorphisms:
113 rs2896218 (NC_000007.14:g.117279924G>A), rs3779550 (NC_000007.14:g.117287306C>T),
114 rs2285544 (NC_000007.14:g.117304229T>A), rs4730775 (NC_000007.14:g.117277064C>T),

115 rs3840660 (NC_000007.14:g.117277191_117277192insA) and rs2024233
116 (NC_000007.14:g.117277373G>A) in strabismus patients and healthy controls. The SNPs
117 rs2896218, rs2285544 and rs3779550 are intronic variants, while rs4730775, rs3840660 and
118 rs2024233 are present in the 3' untranslated region (3' UTR). Three of these variants, rs2896218,
119 rs2285544 and rs2024233 were previously found to be associated with strabismus,⁷ however, the
120 results were not stratified based on clinical subtypes, esotropia and exotropia. Thus, we screened
121 *WNT2* polymorphisms in the Pakistani cohort to ascertain their association with strabismus as
122 well as with its clinical subtypes.

123 **Genotyping**

124 To screen the selected variants, two methods were employed. Tetra-primer amplification
125 refractory mutation system-polymerase chain reaction (tetra-ARMS-PCR) technique was used
126 for the genotyping of SNPs, rs2896218, rs3779550 and rs2285544. Primers were designed
127 following the protocol as described by Medrano & de Oliveira (2014)¹⁶ (Supplementary Table
128 1). About 5% of the samples for each genotype were repeated for cross-verification of the
129 genotyping results. For the other three SNPs, rs4730775, rs3840660 and rs2024233, which were
130 within 500 bp, the Sanger sequencing method was used for genotyping. A total of 66 control and
131 106 strabismus cases (53 esotropic and 53 exotropic) were sequenced to genotype these three
132 polymorphisms. The sequencing was carried out by the Nevada Genomics Center at the
133 University of Nevada, Reno (<https://www.unr.edu/genomics>) and the results were viewed using
134 SnapGene Viewer (v.6.2.2). All PCR reactions were done using Q5[®] Hot Start High-Fidelity 2X
135 Master Mix (New England Biolabs, Inc.). The PCR products were separated on standard agarose
136 gels (2%) in TAE buffer and visualized on a Bio-Rad Gel Doc XR system.

137 **Statistical Analysis**

138 Hardy Weinberg Equilibrium (HWE) test and Principal Component Analysis (PCA) were
139 performed to test for the population structure of the cohort. Linkage Disequilibrium (LD) was
140 computed to detect the possible linkage between the studied SNPs. Logistic regression analysis
141 under additive, dominant and recessive genetic models was applied where all the SNPs were
142 tested for strabismus (strabismus vs. control), esotropia (esotropia vs. control) and exotropia
143 (exotropia vs. control). In addition, analysis was done after dividing the strabismus group into
144 subgroups based on demographic characteristics including age at diagnosis, family history of

145 strabismus, consanguinity among parents, and exposure to passive smoking. All tests were
146 computed using R statistical software (v.4.2.0).¹⁷ Haplotypes were generated from the obtained
147 genotypes using Beagle (beagle.08Feb22.fa4.jar). An online tool
148 (<https://statpages.info/ctab2x2.html>) was used to calculate the odds ratios, 95% confidence
149 interval and p-values between strabismus and controls for each haplotype combination.

150 **Results**

151 **Cohort overview**

152 A total of 315 strabismic patients (141 esotropic and 162 exotropic) and 230 controls were
153 included in this study. In the strabismus group, 52.9% were males, while in the controls 64.3%
154 were males. The mean age of subjects in the strabismus and control groups was 16.4 and 28.2
155 years, respectively. Out of the total strabismus cohort 52.1% were diagnosed at birth, 50.9% had
156 a positive family history of strabismus, and 67.1% subjects reported consanguinity among
157 parents (Supplementary Table 2).

158 **Hardy Weinberg Equilibrium (HWE) and Principal Component Analysis (PCA)**

159 Among the studied variants, only rs4730775, rs3840660 and rs2024233 were found to be in
160 HWE with a p-value of 0.21, 0.76 and 0.54, respectively. However, the genotype frequencies of
161 variants rs2896218, rs3779550 and rs2285544 did not match those expected from the HWE (p-
162 value= \leq 0.00001). The result from PCA revealed no stratification of the control group in the
163 present cohort with 1000 Genomes data; although, a separate cluster was seen for the strabismus
164 group (Supplementary Figure 1). However, the minor allele frequencies (MAF) of rs2896218,
165 rs3779550 and rs2024233 in the present control group were significantly different from that
166 reported for MAF in the Punjabi cohort from Lahore, Pakistan (PJL) dataset (Supplementary
167 Table 3).

168 **Linkage Disequilibrium Analysis**

169 Linkage disequilibrium analysis in the control group of the studied cohort revealed linkage
170 between rs2896218, rs3779550 and rs2285544. In addition, the SNPs rs4730775 and rs3840660
171 were found to be linked, while rs3840660 and rs2024233 were in linkage disequilibrium
172 (Supplementary Table 4).

173 **Association of *WNT2* polymorphisms with strabismus**

174 Logistic regression analysis under the dominant model showed significant protective association
175 of rs2896218 [Odds Ratio (OR)=0.75 (95% Confidence Interval (CI)=0.66 - 0.86), p-
176 value=5.08e-05] and rs2285544 [OR=0.89 (95% CI=0.81 - 0.97), p-value=0.01], while there was
177 significant risk association of rs3779550 [OR=1.17 (95% CI=1.00 - 1.36), p-value= 0.04] and
178 rs4730775 [OR=1.15 (95% CI=1.00- 1.33), p-value=0.05] (Table 1).

179 When adjusted for age and gender, rs2896218 [OR=0.79 (95% CI=0.70 - 0.89), p-value=
180 0.00017], rs2285544 [OR=0.92 (95% CI=0.85 - 0.99), p-value=0.05] and rs4730775 [OR=1.13
181 (95% CI=1.00 - 1.27), p-value=0.05] retained their significance.

182 The variant rs4730775 also showed risk association with strabismus under the additive model
183 [OR=1.10 (95% CI=1.00- 1.21), p-value=0.05]. However, no association was observed for any
184 of the SNPs under the recessive model.

185 **Association of *WNT2* polymorphisms with strabismus subtypes**

186 When strabismus subtypes were separately analyzed, a significant protective association was
187 found for rs2896218 and rs2285544 with both esotropia and exotropia under the dominant
188 model. However, rs4730775 showed significant risk association only with exotropia [OR=1.19
189 (95% CI=1.00 - 1.43), p-value=0.05], which was further strengthened after adjusting for age and
190 gender [OR=1.22 (95% CI=1.04 - 1.42), p-value=0.01].The variant rs3840660 also showed
191 significant risk association with exotropia under dominant model but only after adjusting for age
192 and gender [OR=1.18 (95% CI=1.01 - 1.38), p-value=0.04] (Table 1).

193 Under the additive model, rs2896218 [OR=0.88 (95% CI)=0.80 - 0.98), p-value= 0.01] and
194 rs2285544 [OR=0.90 (95% CI=0.81 - 0.99), p-value= 0.04] showed protective association with
195 esotropia, while rs4730775 [OR=1.14 (95% CI=1.01 - 1.28), p-value= 0.03] and rs3840660
196 [OR=1.14 (95% CI=1.00 - 1.28), p-value=0.04] were found to be risk associated with exotropia.
197 No association was found between rs2024233 and strabismus or any of its subtypes (Table 1).

198 **Association of *WNT2* polymorphisms with strabismus based on demographic features**

199 To determine whether the demographic risk factors influenced the association of the studied
200 variants, we stratified the strabismus group based on the age at diagnosis, family history, parental

201 consanguinity and exposure to smoke. The results revealed significant protective association of
202 rs2896218 and rs2285544, and risk association of rs4730775 with strabismus patients diagnosed
203 at birth while no association was observed for any variant with strabismus patients diagnosed
204 later in life (Table 2).

205 It was also observed that rs2896218 and rs2285544 showed significant protective association,
206 while rs3840660 showed risk association with strabismus patients with a positive family history.
207 The SNP rs3779550 showed protective association with patients with no family history (Table
208 3). Based on consanguinity, rs2896218 and rs3779550 showed an overall risk association with
209 strabismus from non-consanguineous families. However, rs3840660 showed risk association and
210 rs2024233 showed protective association with esotropia in strabismus in consanguineous parents
211 (Table 4). Similarly, no association was observed between the studied variants and strabismus
212 with a positive smoking exposure status. However, rs2285544 showed protective association
213 with overall strabismus with no smoking exposure (Table 5).

214 **Haplotype Analysis**

215 Haplotype analysis was conducted from the obtained genotype data for rs2896218, rs3779550
216 and rs2285544, to see whether any haplotype combination was associated with strabismus. A
217 total of eight haplotype combinations were obtained with one being a rare haplotype (total
218 frequency = 0.007). It was found that the haplotype A T T (corresponding to rs2896218,
219 rs3779550 and rs2285544, respectively), was significantly more prevalent in the strabismus
220 group with a p-value=0.001 (Table 6). Another haplotype, A T A, was more prevalent in the
221 control group (p-value=0.006). In addition to these, two other haplotypes, G C A and A C A
222 tended to be associated with strabismus and control groups, respectively (p-values=0.05).

223 **Discussion**

224 Comitant strabismus (CS) is a common condition comprising more than 95% of all strabismus
225 cases. Recent studies have identified candidate genes associated with CS, including *LRP2*, *WRB*,
226 *MGST2*, *WNT*, *FOXG1* and *IGF1*.^{4-7,18} The *WNT2* gene is located at the 7q31.2 locus, which has
227 been previously identified as a susceptibility locus for CS including both of its subtypes,
228 esotropia and exotropia.^{14,19} Later, another study revealed association of *WNT2* polymorphisms,
229 rs2896218, rs2285544 and rs2024233, with strabismus in a Japanese cohort.⁷ However, their

230 results were not stratified based on esotropia and exotropia. In the current study we screened six
231 SNPs of *WNT2* in strabismus patients of Pakistani origin, out of which four were found to be
232 associated with strabismus and one of its subtypes.

233 Our results revealed a significant protective association of rs2896218 and rs2285544 with
234 esotropia, while disease association was observed for rs4730775 and rs3840660 with exotropia.
235 However, rs2024233 was not associated with any strabismus subtype.

236 The polymorphism rs4730775 has previously been implicated in fibrosis of musculoskeletal
237 tissues in diseases such as Dupuytren's disease.^{20,21} Fibrosis of extraocular muscles (EOMs) has
238 also been observed in incommittant forms of strabismus.²² While the specific role of *WNT2* in
239 fibrosis of the EOM is not well-established, it is known that the WNT signalling pathway is
240 involved in the regulation of tissue fibrosis in general. WNT signalling has also been implicated
241 in the development of fibrotic conditions in various organs, including the lungs, liver, and
242 skin.²³⁻²⁵ Dysregulation of WNT signalling can contribute to the activation of fibroblasts, the
243 production of excessive extracellular matrix (ECM) proteins (collagens), and the development of
244 fibrosis.²⁶ Moreover, the ECM stiffness impacts the expression of genes involved in the Wnt/ β -
245 catenin pathway, thus resulting in a positive feedback loop.²⁷ We have previously reported that
246 the expression of ECM-related genes, especially collagens, are altered in strabismic EOMs,²⁸ an
247 observation which was also reported by Agarwal et al., (2016)²⁹ and Altick et al., (2012).³⁰ ECM
248 also regulates the cell differentiation and mineralization of tissues during craniofacial
249 development.³¹ Barreto et al. (2017)³² has shown that stiffer substrates can accelerate bone
250 formation and suggested that ECM stiffness could lead to premature bone ossification in
251 craniosynostosis, a condition characterized by the premature fusion of bones of the skull thus
252 restricting brain growth and development. Aberrations in WNT signalling have also been
253 reported in craniosynostosis,³³⁻³⁵ while *WNT2* was found to be dysregulated in Apert syndrome,
254 a genetic condition characterized by fusion of the skull, hands, and feet bones.³⁶ Strabismus is
255 the most prevalent ocular abnormality in both non-syndromic and syndromic craniosynostosis,
256 including Apert and Crouzon syndromes.³⁷ It is possible that *WNT2*-induced differences in facial
257 and orbital anatomy may contribute to an altered frequency of strabismus and its subtypes.

258 The prevalence of strabismus is also increased in certain neurological conditions including
259 autism spectrum disorder (ASD) compared to the general population.³⁸ A recent study has

260 implicated the involvement of *WNT2* polymorphisms with altered cortical thickness in patients
261 with ASD.³⁹ Altered cortical thickness has also been reported in CS patients.⁴⁰ Thus, it is possible
262 that errors in early development of the brain may cause strabismus, however further studies
263 exploring brain development in CS are needed to establish the role of *WNT2* polymorphisms in
264 strabismus causation.

265 A total of six polymorphisms were screened in the present study, out of which only three i.e.,
266 rs4730775, rs3840660 and rs2024233 were found to be in HWE. The principle of HWE assumes
267 that there is no mutation, no selection, no gene flow, infinite population size and random mating.
268 Though the sample size for this study was appropriate (according to <https://www.calculator.net/>)
269 it could be one of the limiting factors in achieving HWE in the studied cohort. Moreover,
270 Pakistan has one of the highest rates of consanguineous marriages (<https://www.consang.net/>)⁴¹
271 and almost half of our samples have positive consanguinity, which could explain the deviation
272 from HWE, which is based on the premise of random mating. Some of the previous studies from
273 our research group also found that the studied variants did not adhere to the HWE,^{18,42} which
274 could indicate inbreeding and population stratification. However, for the present study, the PCA
275 analysis showed no population stratification for the control cohort used. A study by Salanti et al.,
276 (2005)⁴³ emphasized that the deviations from HWE in genetic association studies are quite
277 common and, in most cases, can be explained by low sample size. The same study cautioned that
278 the lack of power in the study cohorts could also make it harder to detect the extent of inbreeding
279 and thus any deviation from HWE.

280 To further validate the protective association of rs2896218 and rs2285544, these variants were
281 found to be benign in terms of disease probability (<https://regsnps-intron.cccb.iupui.edu/>).
282 However, the variant rs2285544 was predicted to activate a new cryptic acceptor splice site
283 (<https://hsf.genomnis.com/home>). This, along with the results of haplotype analysis, further
284 strengthens the possibility of a specific combination of variants and interactions among multiple
285 genetic markers influencing the disease phenotype. Future genetic and proteomic studies on the
286 *WNT2* gene may be helpful in exploring this idea further.

287 We compared allele frequencies of the studied control cohort to the PJJ dataset from the 1000
288 Genomes project and found significant differences for three of the variants i.e., rs2896218,
289 rs3779550 and rs2024233. Hashmi et al., (2022)⁴⁴ and Khan et al., (2020)⁴² from our research

290 group reported similar observations, one reason for this could be that the majority of the samples
291 collected for this and the previous studies were from the twin cities of Rawalpindi and
292 Islamabad. Both these cities comprise people from diverse backgrounds including a high influx
293 of Pashtuns from Khyber Pakhtunkhwa. The PJJ dataset consists of samples from Lahore, which
294 is approximately 400km distant from the twin cities and mostly contains Punjabi ethnic group.
295 The differences of the current cohort from the PJJ dataset suggest that the population in the twin
296 cities is heterogenous as compared to the PJJ reference dataset. Moreover, the variants screened
297 in the present study are in the non-coding region so their corresponding genotypes in the PJJ
298 dataset are derived from low coverage whole genome sequencing data, which does not produce
299 high-quality genotypes.⁴² The number of samples in the PJJ dataset is also low as compared to
300 our control cohort, thus further underpowering their results.

301 The LD pattern obtained for the PJJ dataset was compared to the LD calculated from the control
302 cohort of the present study, which also indicated some differences. The controls collected for this
303 study were carefully selected to only include healthy individuals without a history of any ocular
304 or systemic condition, but the same criteria could not be verified for the PJJ dataset. Thus, the
305 observed differences could be a result of ‘non-random’ sampling of controls for the present
306 study. The results of our PCA analysis show that the control group did not cluster separately
307 from the overall 1000 Genomes data, confirming that the current control group is a reliable
308 representation of an overall unaffected population. However, we did observe a separate cluster
309 for the strabismus group indicating that this is indeed different from the overall 1000 Genomes
310 data.

311 The results of the present study suggest an involvement of *WNT2* polymorphisms with
312 strabismus. Being an early developmental gene, it supports the idea that strabismus develops as a
313 result of abnormal muscle architecture and signaling defects during embryonic development. The
314 fact that the association of the studied variants (rs2896218, rs2285544 and rs4730775) was only
315 observed in strabismus cases that were diagnosed at birth and not in the patient group diagnosed
316 later in life, strengthens this conjecture. In addition, the results of our haplotype analysis suggest
317 that the presence and combination of multiple variants may influence the severity of the
318 condition. Nevertheless, many individuals develop strabismus later in life, indicating a
319 heterogenous nature of the disease. It is possible that different underlying mechanisms are at play

320 affecting different stages of muscle development and regeneration capacities or alterations in
321 visual or motor pathways,⁴⁵ ultimately leading to a similar phenotype. Thus, there is a need for
322 extensive genetic studies to further investigate how genetic variations influence strabismus.
323 Moreover, familial studies using high throughput techniques and functional studies must be
324 carried out to identify the genetic variants playing a major role in strabismus causation.

325 **References**

- 326 1. Hashemi H, Pakzad R, Heydarian S, *et al.* Global and regional prevalence of strabismus: a
327 comprehensive systematic review and meta-analysis. *Strabismus* 2019;**27**:54-65.
328 doi:10.1080/09273972.2019.1604773
- 329 2. Agarwal AB, Cassinelli K, Johnson LA, *et al.* Seasonality of births in horizontal
330 strabismus: comparison with birth seasonality in schizophrenia and other disease
331 conditions. *J Dev Orig Health Dis* 2019;**10**:636-644. doi:10.1017/S2040174419000102.
332 Seasonality
- 333 3. Maconachie GDE, Gottlob I, McLean RJ. Risk Factors and Genetics in Common
334 Comitant Strabismus. *JAMA Ophthalmol* 2013;**131**:1179-1186.
335 doi:10.1001/jamaophthalmol.2013.4001
- 336 4. Shaaban S, Mackinnon S, Andrews C, *et al.* Genome-Wide Association Study Identifies a
337 Susceptibility Locus for Comitant Esotropia and Suggests a Parent-of-Origin Effect.
338 *Invest Ophthalmol Vis Sci* 2018;**59**:4054-4064. doi:10.1167/iovs.18-24082
- 339 5. Wang Y, Chen X, Jiang T, *et al.* Expanding the phenotypic spectrum of mutations in
340 LRP2 : a novel candidate gene of non-syndromic familial comitant strabismus. *J Transl*
341 *Med* 2021;**19**:1-11. doi:10.1186/s12967-021-03155-z
- 342 6. Ye X (Cynthia), Roslin NM, Paterson AD, *et al.* Linkage analysis identifies an isolated
343 strabismus locus at 14q12 overlapping with FOXG1 syndrome region. *J Med Genet*
344 2022;**59**:46-55. doi:10.1136/jmedgenet-2020-107226
- 345 7. Zhang J, Matsuo T. MGST2 and WNT2 are candidate genes for comitant strabismus
346 susceptibility in Japanese patients. *PeerJ* 2017;**Oct 17**:e3935. doi:10.7717/peerj.3935
- 347 8. Mulligan KA, Cheyette BNR. Wnt Signaling in Vertebrate Neural Development and
348 Function. *J neuroimmune Pharmacol* 2012;**7**:774-787. doi:10.1007/s11481-012-9404-
349 x.Wnt
- 350 9. Fuhrmann S. Wnt signaling in eye organogenesis. *Organogenesis* 2008;**4**:60-67.
351 doi:10.4161/org.4.2.5850

- 352 10. Cisternas P, Henriquez JP, Brandan E, Inestrosa NC. Wnt Signaling in Skeletal Muscle
353 Dynamics: Myogenesis , Neuromuscular Synapse and Fibrosis. *Mol Neurobiol*
354 2013;**49**:574–589. doi:10.1007/s12035-013-8540-5
- 355 11. Fedon Y, Bonnieu A, Gay S, Vernus B, Bacou F, Bernardi H. Role and Function of Wnts
356 in the Regulation of Myogenesis: When Wnt Meets Myostatin. In: *Skeletal Muscle - From*
357 *Myogenesis to Clinical Relations*. InTech; 2012. doi:10.5772/48330
- 358 12. Onizuka T, Yuasa S, Kusumoto D, *et al.* Wnt2 accelerates cardiac myocyte differentiation
359 from ES-cell derived mesodermal cells via non-canonical pathway. *J Mol Cell Cardiol*
360 2012;**52**:650-659. doi:10.1016/j.yjmcc.2011.11.010
- 361 13. Sousa KM, Villaescusa JC, Cajanek L, *et al.* Wnt2 Regulates Progenitor Proliferation in
362 the Developing Ventral Midbrain. *J Biol Chem* 2010;**285**:7246-7253.
363 doi:10.1074/jbc.M109.079822
- 364 14. Shaaban S, Matsuo T, Fujiwara H, *et al.* Chromosomes 4q28.3 and 7q31.2 as New
365 Susceptibility Loci for Comitant Strabismus. *Invest Ophthalmol Vis Sci* 2009;**50**:654-661.
366 doi:10.1167/iovs.08-2437
- 367 15. Sambrook J, Russell DW. *Molecular Cloning: A Laboratory Manual*. Vol 1. 3rd ed. New
368 York: Cold Spring Harbor Laboratory Press; 2001.
- 369 16. Medrano RFV, de Oliveira CA. Guidelines for the Tetra-Primer ARMS–PCR Technique
370 Development. *Mol Biotechnol* 2014;**56**:599-608. doi:10.1007/s12033-014-9734-4
- 371 17. R Core Team. R: A Language and Environment for Statistical Computing. 2022.
- 372 18. Zehra Z, Khan N, Nadeem M, *et al.* Association of IGF1 polymorphisms with exotropia in
373 a Pakistani cohort. *Mol Vis* 2022;**28**:369-377.
- 374 19. Fujiwara H, Matsuo T, Sato M, *et al.* Genome-wide search for strabismus susceptibility
375 loci. *Acta Med Okayama* 2003;**57**:109-116.
- 376 20. Dolmans GH, Werker PM, Hennies HC, *et al.* Wnt Signaling and Dupuytren’s Disease. *N*
377 *Engl J Med* 2011;**365**:307-317. doi:10.1056/NEJMoa1101029
- 378 21. Anderson ER, Ye Z, Caldwell MD, Burmester JK. SNPs Previously Associated with

- 379 Dupuytren's Disease Replicated in a North American Cohort. *Clin Med Res* 2014;**12**:133-
380 137. doi:10.3121/cm.2013.1199
- 381 22. Wang SM, Zwaan J, Mullaney PB, *et al.* Congenital fibrosis of the extraocular muscles
382 type 2, an inherited exotropic strabismus fixus, maps to distal 11q13. *Am J Hum Genet*
383 1998;**63**:517-525. doi:10.1086/301980
- 384 23. Baarsma HA, Königshoff M. 'WNT-er is coming': WNT signalling in chronic lung
385 diseases. *Thorax* 2017;**72**:746-759. doi:10.1136/thoraxjnl-2016-209753
- 386 24. Nishikawa K, Osawa Y, Kimura K. Wnt/ β -Catenin Signaling as a Potential Target for the
387 Treatment of Liver Cirrhosis Using Antifibrotic Drugs. *Int J Mol Sci* 2018;**19**:3103.
388 doi:10.3390/ijms19103103
- 389 25. Griffin MF, Huber J, Evan FJ, Quarto N, Longaker MT. The role of Wnt signaling in skin
390 fibrosis. *Med Res Rev* 2022;**42**:615-628. doi:10.1002/med.21853
- 391 26. Działo E, Czepiel M, Tkacz K, Siedlar M, Kania G, Błyszczuk P. WNT/ β -Catenin
392 Signaling Promotes TGF- β -Mediated Activation of Human Cardiac Fibroblasts by
393 Enhancing IL-11 Production. *Int J Mol Sci* 2021;**22**:10072. doi:10.3390/ijms221810072
- 394 27. Du J, Zu Y, Li J, *et al.* Extracellular matrix stiffness dictates Wnt expression through
395 integrin pathway. *Sci Rep* 2016;**6**:20395. doi:10.1038/srep20395
- 396 28. Zehra Z, von Bartheld CS, Azam M, Qamar R. Expression profiling of extracellular
397 matrix related genes in patients with strabismus. *Clin Experiment Ophthalmol*
398 2023;**51**:646-649. doi:10.1111/ceo.14242
- 399 29. Agarwal AB, Feng CY, Altick AL, *et al.* Altered protein composition and gene expression
400 in strabismic human extraocular muscles and tendons. *Investig Ophthalmol Vis Sci*
401 2016;**57**:5576-5585. doi:10.1167/iovs.16-20294
- 402 30. Altick AL, Feng C, Schlauch K, Johnson LA, von Bartheld CS. Differences in Gene
403 Expression between Strabismic and Normal Human Extraocular Muscles. *Invest*
404 *Ophthalmol Vis Sci* 2012;**53**:5168-5177. doi:10.1167/iovs.12-9785
- 405 31. Cruz Walma DA, Yamada KM. Extracellular Matrix in Human Craniofacial

- 406 Development. *J Dent Res* 2022;**101**:495-504. doi:10.1177/002203452111052982
- 407 32. Barreto S, González-Vázquez A, R. Cameron A, O'Brien FJ, Murray DJ. Identification of
408 stiffness-induced signalling mechanisms in cells from patent and fused sutures associated
409 with craniosynostosis. *Sci Rep* 2017;**7**:11494. doi:10.1038/s41598-017-11801-0
- 410 33. Behr B, Longaker MT, Quarto N. Differential activation of canonical Wnt signaling
411 determines cranial sutures fate: A novel mechanism for sagittal suture craniosynostosis.
412 *Dev Biol* 2010;**344**:922-940. doi:10.1016/j.ydbio.2010.06.009
- 413 34. Maruyama T, Mirando AJ, Deng C-X, Hsu W. The Balance of WNT and FGF Signaling
414 Influences Mesenchymal Stem Cell Fate During Skeletal Development. *Sci Signal* 2010;**3**.
415 doi:10.1126/scisignal.2000727
- 416 35. Stamper BD, Park SS, Beyer RP, *et al.* Differential Expression of Extracellular Matrix-
417 Mediated Pathways in Single-Suture Craniosynostosis. *PLoS One* 2011;**6**:e26557.
418 doi:10.1371/journal.pone.0026557
- 419 36. Çetinkaya A, Taşkiran E, Soyer T, *et al.* Dermal fibroblast transcriptome indicates
420 contribution of wnt signaling pathways in the pathogenesis of apert syndrome. *Turk J*
421 *Pediatr* 2017;**59**:619. doi:10.24953/turkjped.2017.06.001
- 422 37. Rostamzad P, Arslan Z, Mathijssen I, *et al.* Prevalence of Ocular Anomalies in
423 Craniosynostosis: A Systematic Review and Meta-Analysis. *J Clin Med* 2022;**11**:1060.
424 doi:10.3390/jcm11041060
- 425 38. Perna J, Bellato A, Ganapathy PS, *et al.* Association between Autism Spectrum Disorder
426 (ASD) and vision problems. A systematic review and meta-analysis. *Mol Psychiatry* July
427 2023. doi:10.1038/s41380-023-02143-7
- 428 39. Chien Y-L, Chen Y-C, Chiu Y-N, Tsai W-C, Gau SS-F. A translational exploration of the
429 effects of *WNT2* variants on altered cortical structures in autism spectrum disorder. *J*
430 *Psychiatry Neurosci* 2021;**46**:E647-E658. doi:10.1503/jpn.210022
- 431 40. Yin X, Chen L, Ma M, *et al.* Altered Brain Structure and Spontaneous Functional Activity
432 in Children With Concomitant Strabismus. *Front Hum Neurosci* 2021;**15**:777762.
433 doi:10.3389/fnhum.2021.777762

- 434 41. Bhinder MA, Sadia H, Mahmood N, *et al.* Consanguinity: A blessing or menace at
435 population level? *Ann Hum Genet* 2019;**83**:214-219. doi:10.1111/ahg.12308
- 436 42. Khan N, Paterson AD, Roshandel D, *et al.* Association of IGF1 and VEGFA
437 polymorphisms with diabetic retinopathy in Pakistani population. *Acta Diabetol*
438 2020;**57**:237-245. doi:10.1007/s00592-019-01407-5
- 439 43. Salanti G, Amountza G, Ntzani EE, Ioannidis JPA. Hardy–Weinberg equilibrium in
440 genetic association studies: an empirical evaluation of reporting, deviations, and power.
441 *Eur J Hum Genet* 2005;**13**:840-848. doi:10.1038/sj.ejhg.5201410
- 442 44. Hashmi AN, Ahmed Dharejo R, Zubair U Bin, *et al.* Association of dopamine β -
443 hydroxylase polymorphism rs1611115 and serum levels with psychiatric disorders in
444 Pakistani population. *Int J Neurosci* September 2022:1-9.
445 doi:10.1080/00207454.2022.2126774
- 446 45. von Bartheld CS, Croes SA, Johnson LA. Strabismus. In: Levin LA, Albert DM, eds.
447 *Ocular Disease: Mechanisms and Management*. Philadelphia, PA: Saunders; 2010:454-
448 460.

449

450 **Acknowledgments**

451 The authors thank all the participants for their contribution in the study.

452 **Funding**

453 This work was supported by a grant from the Higher Education Commission, Pakistan,
454 “International Research Support Initiative” to ZZ, and a grant from the National Institutes of
455 Health (GM103554) to CSvB and GM104944 and GM103440 to HV-G.

456 Table 1: Logistic regression analysis results for the studied variants. Statistically significant p-values are indicated in bold font.

		Univariable Logistic Regression Analysis						Logistic Regression Analysis (adjusted for age and gender)					
SNP	Model	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p
rs2896218	Additive	0.94 (0.87 - 1.02)	0.14	0.88 (0.80 - 0.98)	0.01	0.99 (0.89 - 1.11)	0.92	0.95 (0.89 - 1.03)	0.21	0.92 (0.85 - 1.01)	0.08	0.98 (0.88 - 1.09)	0.73
	Recessive	1.08 (0.96 - 1.20)	0.21	1.07 (0.93 - 1.23)	0.31	1.08 (0.94 - 1.24)	0.26	1.07 (0.97 - 1.19)	0.18	1.09 (0.97 - 1.23)	0.16	1.08 (0.96 - 1.24)	0.19
	Dominant	0.75 (0.66 - 0.86)	<0.01	0.65 (0.56 - 0.76)	<0.01	0.81 (0.66 - 1.00)	0.05	0.79 (0.70 - 0.89)	<0.01	0.71 (0.62 - 0.82)	<0.01	0.76 (0.62 - 0.92)	<0.01
rs3779550	Additive	1.12 (0.97 - 1.28)	0.12	1.09 (0.94 - 1.26)	0.27	1.11 (0.96 - 1.29)	0.17	1.02 (0.91 - 1.16)	0.72	1.00 (0.87 - 1.15)	0.94	1.02 (0.88 - 1.18)	0.81
	Recessive	0.82 (0.55 - 1.23)	0.35	0.89 (0.59 - 1.34)	0.50	0.84 (0.55 - 1.29)	0.43	0.92 (0.63 - 1.33)	0.64	0.94 (0.63 - 1.40)	0.76	0.89 (0.58 - 1.36)	0.59
	Dominant	1.17 (1.00 - 1.36)	0.04	1.12 (0.96 - 1.32)	0.15	1.16 (0.99 - 1.37)	0.07	1.04 (0.91 - 1.19)	0.58	1.01 (0.87 - 1.18)	0.85	1.04 (0.89 - 1.21)	0.64
rs2285544	Additive	0.92 (0.85 - 1.00)	0.06	0.90 (0.81 - 0.99)	0.04	0.93 (0.85 - 1.03)	0.17	0.94 (0.87 - 1.01)	0.10	0.95 (0.87 - 1.03)	0.20	0.93 (0.85 - 1.02)	0.12
	Recessive	1.31 (0.96 - 1.79)	0.09	1.17 (0.73 - 1.87)	0.50	1.43 (0.99 - 2.05)	0.05	1.10 (0.83 - 1.46)	0.49	1.09 (0.73 - 1.62)	0.69	1.21 (0.87 - 1.68)	0.26
	Dominant	0.89 (0.81 - 0.97)	0.01	0.88 (0.79 - 0.98)	0.02	0.89 (0.81 - 0.99)	0.04	0.92 (0.85 - 0.99)	0.05	0.94 (0.85 - 1.03)	0.16	0.90 (0.82 - 0.99)	0.04
rs4730775	Additive	1.10 (1.00 - 1.21)	0.05	1.08 (0.95 - 1.22)	0.22	1.14 (1.01 - 1.28)	0.03	1.07 (0.99 - 1.16)	0.08	1.05 (0.95 - 1.16)	0.34	1.14 (1.03 - 1.26)	0.01
	Recessive	1.14 (0.94 - 1.38)	0.19	1.09 (0.84 - 1.41)	0.52	1.22 (0.96 - 1.54)	0.10	1.07 (0.91 - 1.25)	0.43	1.08 (0.88 - 1.33)	0.48	1.17 (0.95 - 1.44)	0.13

	Dominant	1.15 (1.00- 1.33)	0.05	1.13 (0.94 - 1.35)	0.19	1.19 (1.00 - 1.43)	0.05	1.13 (1.00 - 1.27)	0.05	1.07 (0.92 - 1.24)	0.38	1.22 (1.04 - 1.42)	0.01
rs3840660	Additive	1.10 (0.99 - 1.21)	0.06	1.08 (0.95 - 1.22)	0.24	1.14 (1.00 - 1.28)	0.04	1.06 (0.98 - 1.16)	0.15	1.04 (0.94 - 1.15)	0.47	1.11 (0.99 - 1.23)	0.06
	Recessive	1.15 (0.95 - 1.39)	0.15	1.14 (0.89 - 1.46)	0.31	1.20 (0.95 - 1.53)	0.13	1.06 (0.90 - 1.25)	0.46	1.09 (0.89 - 1.34)	0.39	1.10 (0.89 - 1.36)	0.39
	Dominant	1.13 (0.98 - 1.31)	0.10	1.09 (0.91 - 1.31)	0.34	1.18 (0.99 - 1.42)	0.07	1.10 (0.97 - 1.25)	0.13	1.03 (0.89 - 1.20)	0.68	1.18 (1.01 - 1.38)	0.04
rs2024233	Additive	0.97 (0.88 - 1.07)	0.56	0.97 (0.86 - 1.09)	0.66	0.97 (0.86 - 1.09)	0.58	0.97 (0.89 - 1.04)	0.42	0.94 (0.86 - 1.04)	0.30	0.97 (0.87 - 1.07)	0.54
	Recessive	0.98 (0.83 - 1.15)	0.78	0.96 (0.78 - 1.18)	0.70	0.99 (0.81 - 1.21)	0.93	0.97 (0.84 - 1.11)	0.62	0.93 (0.79 - 1.10)	0.41	0.99 (0.83 - 1.19)	0.94
	Dominant	0.95 (0.81 - 1.11)	0.50	0.97 (0.79 - 1.18)	0.74	0.92 (0.76 - 1.12)	0.41	0.95 (0.83 - 1.08)	0.40	0.93 (0.79 - 1.09)	0.37	0.92 (0.78 - 1.09)	0.35

457 ¹ Strabismus vs Controls, ² Esotropia vs Controls, ³ Exotropia vs Controls

458 CI, confidence interval; OR, odds ratio

459 Table 2: Univariate regression for strabismus diagnosed at birth and diagnosed later when compared to controls separately (Additive
 460 model). Statistically significant p-values are indicated in bold font.

SNP	Strabismus Diagnosed at Birth vs Control						Strabismus Diagnosed Later vs Control					
	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p
rs2896218	0.83 (0.73 - 0.94)	<0.01	0.84 (0.76 - 0.92)	<0.01	0.93 (0.82 - 1.05)	0.23	0.97 (0.86 - 1.09)	0.63	0.94 (0.85 - 1.03)	0.19	1.07 (0.97 - 1.17)	0.21
rs3779550	1.13 (0.98 - 1.31)	0.08	0.99 (0.89 - 1.10)	0.96	1.09 (0.96 - 1.26)	0.19	1.07 (0.92 - 1.23)	0.39	1.05 (0.93 - 1.18)	0.42	1.01 (0.91 - 1.14)	0.80
rs2285544	0.89 (0.81 - 0.99)	0.04	0.95 (0.88 - 1.03)	0.21	0.91 (0.83 - 1.00)	0.06	0.93 (0.83 - 1.03)	0.15	0.92 (0.85 - 1.00)	0.05	1.03 (0.95 - 1.11)	0.51
rs4730775	1.14 (1.00 - 1.30)	0.05	1.15 (1.02 - 1.31)	0.03	1.06 (0.93 - 1.21)	0.38	0.97 (0.85 - 1.11)	0.69	1.02 (0.90 - 1.14)	0.80	0.93 (0.84 - 1.04)	0.22
rs3840660	1.13 (0.98 - 1.29)	0.09	1.11 (0.98 - 1.26)	0.11	1.08 (0.94 - 1.23)	0.28	0.99 (0.87 - 1.13)	0.95	1.02 (0.90- 1.15)	0.80	0.97 (0.87 - 1.08)	0.59
rs2024233	0.96 (0.85 - 1.09)	0.57	0.94 (0.83 - 1.05)	0.28	1.01 (0.89 - 1.14)	0.94	1.09 (0.97 - 1.22)	0.16	1.05 (0.94 - 1.18)	0.36	1.07 (0.97 - 1.17)	0.17
rs2244352	0.98 (0.90 - 1.07)	0.67	0.99 (-0.93) (1.07)	0.99	0.98 (0.91 - 1.07)	0.69	1.03 (0.95 - 1.12)	0.45	1.02 (0.96 - 1.09)	0.52	1.02 (0.96 - 1.09)	0.46

461 ¹ Strabismus vs Controls, ² Esotropia vs Controls, ³ Exotropia vs Controls

462 CI, confidence interval; OR, odds ratio

463 Table 3: Univariate regression for strabismus cases with positive family history and no family history when compared to controls
 464 separately (Additive model). Statistically significant p-values are indicated in bold font.

SNP	Strabismus with Positive Family History vs Controls						Strabismus with No Family History vs Controls					
	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p
rs2896218	0.88 (0.79 - 0.97)	0.01	0.85 (0.77 - 0.94)	<0.01	0.96 (0.87 - 1.07)	0.50	0.98 (0.88 - 1.09)	0.68	0.92 (0.84 - 1.02)	0.11	1.04 (0.93 - 1.17)	0.46
rs3779550	1.04 (0.90 - 1.19)	0.60	1.00 (0.89 - 1.12)	0.99	1.07 (0.95 - 1.20)	0.28	1.16 (0.99 - 1.36)	0.05	1.09 (0.96 - 1.23)	0.17	1.10 (0.96 - 1.26)	0.17
rs2285544	0.89 (0.82 - 0.99)	0.03	0.89 (0.82 - 0.98)	0.01	0.97 (0.89 - 1.04)	0.42	0.93 (0.84 - 1.03)	0.15	0.95 (0.88 - 1.04)	0.26	0.96 (0.87 - 1.05)	0.34
rs4730775	1.13 (0.99 - 1.29)	0.06	1.06 (0.94 - 1.21)	0.34	1.14 (1.01 - 1.29)	0.03	1.03 (0.90 - 1.17)	0.71	1.06 (0.94 - 1.20)	0.34	0.98 (0.86 - 1.11)	0.71
rs3840660	1.16 (1.02 - 1.32)	0.02	1.09 (0.97 - 1.23)	0.16	1.15 (1.02 - 1.30)	0.02	0.98 (0.86 - 1.13)	0.80	0.98 (0.87 - 1.12)	0.80	0.99 (0.87 - 1.13)	0.89
rs2024233	0.91 (0.81 - 1.03)	0.14	0.92 (0.82 - 1.03)	0.15	0.95 (0.84 - 1.07)	0.42	1.10 (0.97 - 1.25)	0.12	1.10 (0.97 - 1.23)	0.13	1.05 (0.94 - 1.19)	0.38
rs2244352	0.98 (0.90 - 1.07)	0.68	0.99 (0.92 - 1.07)	0.81	1.00 (0.93 - 1.08)	0.97	1.02 (0.94 - 1.11)	0.60	1.02 (0.96 - 1.10)	0.51	1.01 (0.93 - 1.09)	0.87

465 ¹ Strabismus vs Controls, ² Esotropia vs Controls, ³ Exotropia vs Controls

466 CI, confidence interval; OR, odds ratio

467 Table 4: Univariate regression for strabismus cases whose parents had a consanguineous marriage and those with non-consanguineous
 468 marriage when compared to controls separately (Additive model). Statistically significant p-values are indicated in bold font.

SNP	Strabismus with Consanguineous Parents vs Controls						Strabismus with Non-Consanguineous Parents vs Controls					
	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p
rs2896218	0.94 (0.85 - 1.04)	0.25	0.87 (0.79 - 0.96)	<0.01	1.03 (0.92 - 1.14)	0.66	0.90 (0.80 - 1.00)	0.05	0.90 (0.81 - 0.99)	0.02	0.97 (0.87 - 1.07)	0.53
rs3779550	0.95 (0.86 - 1.05)	0.35	1.01 (0.89 - 1.15)	0.84	1.11 (0.96 - 1.28)	0.15	1.15 (1.00 - 1.33)	0.04	1.06 (0.95 - 1.18)	0.31	1.11 (0.99 - 1.25)	0.08
rs2285544	1.07 (0.93 - 1.24)	0.34	0.94 (0.85 - 1.02)	0.15	0.99 (0.90 - 1.09)	0.91	0.93 (0.84 - 1.02)	0.13	0.98 (0.90 - 1.06)	0.55	0.94 (0.87 - 1.02)	0.12
rs4730775	1.09 (0.96 - 1.23)	0.17	1.12 (0.99 - 1.27)	0.06	1.03 (0.91 - 1.18)	0.63	1.11 (0.97 - 1.26)	0.13	1.04 (0.91 - 1.18)	0.55	1.12 (0.99 - 1.27)	0.07
rs3840660	1.10 (0.97 - 1.24)	0.12	1.15 (1.02 - 1.29)	0.03	1.02 (0.90 - 1.17)	0.73	1.08 (0.94 - 1.24)	0.26	1.00 (0.88 - 1.14)	0.98	1.13 (1.00 - 1.28)	0.06
rs2024233	0.90 (0.80 - 1.01)	0.08	0.87 (0.77 - 0.98)	0.02	0.97 (0.86 - 1.09)	0.58	1.12 (0.99 - 1.28)	0.07	1.11 (0.99 - 1.25)	0.09	1.06 (0.95 - 1.19)	0.32
rs2244352	0.99 (0.91 - 1.07)	0.77	0.99 (0.92 - 1.08)	0.95	0.99 (0.92 - 1.08)	0.94	1.02 (0.94 - 1.11)	0.66	1.02 (0.95 - 1.09)	0.58	1.00 (0.93 - 1.08)	0.94

469 ¹ Strabismus vs Controls, ² Esotropia vs Controls, ³ Exotropia vs Controls

470 CI, confidence interval; OR, odds ratio

471 Table 5: Univariate regression for strabismus cases who had intrauterine or early infancy exposure to cigarette smoke and those with
 472 no smoking exposure when compared to controls separately (Additive model). Statistically significant p-values are indicated in bold
 473 font.

SNP	Strabismus with Smoking Exposure vs Controls						Strabismus with No Smoking Exposure vs Controls					
	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p	¹ OR (95%CI)	¹ p	² OR (95%CI)	² p	³ OR (95%CI)	³ p
rs2896218	0.92 (0.83 - 1.03)	0.14	0.92 (0.85 - 1.00)	0.06	0.97 (0.88 - 1.08)	0.60	0.95 (0.86 - 1.06)	0.36	0.91 (0.82 - 1.00)	0.06	1.02 (0.91 - 1.14)	0.74
rs3779550	1.07 (0.94 - 1.22)	0.30	1.01 (0.92 - 1.11)	0.83	1.07 (0.96 - 1.20)	0.24	1.09 (0.94 - 1.26)	0.24	1.04 (0.92 - 1.17)	0.55	1.11 (0.96 - 1.27)	0.15
rs2285544	0.96 (0.88- 1.05)	0.33	0.97 (0.91 - 1.04)	0.41	0.97 (0.90 - 1.05)	0.42	0.90 (0.81 - 0.99)	0.03	0.96 (0.88 - 1.05)	0.35	0.91 (0.83 - 0.99)	0.05
rs4730775	1.12 (0.98 - 1.28)	0.08	1.11 (0.99 - 1.24)	0.07	1.05 (0.93 - 1.19)	0.42	0.99 (0.87- 1.13)	0.90	1.01 (0.88 - 1.15)	0.91	0.98 (0.86 - 1.11)	0.72
rs3840660	1.08 (0.95 - 1.24)	0.25	1.05 (0.93 - 1.17)	0.43	1.06 (0.94 - 1.19)	0.36	1.04 (0.91 - 1.18)	0.61	1.03 (0.91 - 1.18)	0.60	1.02 (0.90 - 1.15)	0.79
rs2024233	1.03 (0.92 - 1.17)	0.59	1.02 (0.92 - 1.14)	0.67	1.02 (0.92 - 1.14)	0.68	1.01 (0.89 - 1.14)	0.92	1.00 (0.89 - 1.13)	0.94	1.00 (0.90 - 1.13)	0.94
rs2244352	1.01 (0.93 - 1.09)	0.85	1.02 (0.97 - 1.08)	0.38	0.99 (0.93 - 1.06)	0.84	1.02 (0.94- 1.11)	0.69	1.03 (0.96 - 1.11)	0.41	1.00 (0.93- 1.08)	0.99

474 ¹ Strabismus vs Controls, ² Esotropia vs Controls, ³ Exotropia vs Controls


475 CI, confidence interval; OR, odds ratio

476 Table 6: Distribution of haplotypes in strabismus and control groups. Statistically significant p-values are indicated in bold font.

Rs2896218	Rs3779550	Rs2285544	In Total (n=291) number (frequency)	In Controls (n=155) Number (frequency)	In Strabismus (n=136) Number (frequency)	OR (95% CI)	P-value
G	T	T	137 (0.24)	77 (0.25)	60 (0.22)	0.86 (0.58 - 1.26)	0.43
G	C	T	110 (0.19)	66 (0.21)	44 (0.16)	0.71 (0.47 - 1.09)	0.14
A	T	T	86 (0.15)	32 (0.10)	54 (0.20)	2.15 (1.34 - 3.45)	<0.01
A	C	A	78 (0.13)	50 (0.16)	28 (0.10)	0.60 (0.36 - 0.98)	0.05
A	C	T	71 (0.12)	32 (0.10)	39 (0.14)	1.45 (0.88 - 2.39)	0.16
G	C	A	59 (0.10)	24 (0.08)	35 (0.13)	1.76 (1.02 - 3.04)	0.05
A	T	A	37 (0.06)	28 (0.09)	9 (0.03)	0.35 (0.16 - 0.74)	<0.01
G	T	A	4 (7.00e-03)	1 (3.00e-03)	3 (0.01)	3.45 (0.36 - 33.36)	0.34

477 CI, confidence interval; OR, odds ratio; n, number of samples analyzed

478 Supplementary Figure 1: Graphical representation of principal component 1 (PC1) plotted
479 against principal component 2 (PC2) after PCA analysis showing a separate cluster for our
480 strabismus cohort (labeled as EXP.STB), while no stratification is observed for our control
481 cohort (labeled as EXP.CTR) with 1000 Genomes data.



482

483 AFR, Africans; AMR, Native Americans; EAS, East Asians; EUR, Europeans; EXP.CTR, Experimental Controls;
484 EXP.STB, Experimental Strabismus; SAS, South Asians.

485 Supplementary Table 1: Sequences and details of the primers used in the present study.

SNPs	Primers (5' – 3')	Annealing Temperature	Product Length (bp)
<i>WNT2</i>			
RS2896218	OF – CACAGATGATCACTATTGCCACTTA	60.4°C	OF-OR = 617 OF-IR = 468 IF-OR = 193
	OR – AATCATTCTGACCAAACGCTG	58.7°C	
	IF – GTCTTCCTTTTGATATCTCTGCCG	62.5°C	
	IR – GAGAGACAGTCACGAGGCCTT	61.0°C	
RS2285544	OF – CTGCTCGTCACTTCTCCTCA	59.3°C	OF-OR = 513 OF-IR = 352 IF-OR = 201
	OR – GCTGCTGAGTGCTGAACAAG	59.9°C	
	IF – CACAGGCTTTTGGCTTCTCAT	61.7°C	
	IR – CAGACTTCCCATCTGCACCT	60.3°C	
RS3779550	OF – CTGTCCCACTGAGGTGACTT	57.7°C	OF-OR = 387 OF-IR = 97 IF-OR = 366
	OR – CAATGCAGCAGATGAGAGTAAC	57.7°C	
	IF – AGCCAAGGTCGTGCAAC	58.3°C	
	IR – CGCCCAGGCTGGAGTATAA	61.1°C	
3'UTR region	F – CAGTATCACATCATCTTGTAAGCATC	59.1°C	828
	R – CTCAAAGGAGCTTTCTCAATGTC	59.5°C	

486 Bp, base pairs; F, Forward Primer; IF, Inner Forward Primer; IR, Inner Reverse Primer; OF, Outer Forward Primer;

487 OR, Outer Reverse Primer; R, Reverse Primer; 3'UTR, 3'untranslated region

488 **Supplementary Table 2: Demographic details of the examined cohorts**

Subjects	Controls	Strabismus	Esotropia	Exotropia
Total (N)	230	315	141	162
Gender (Male) (%)	64.25	52.90	52.48	53.70
Age (Years) (mean (±SD))*	28.21 (±12.39)	16.39 (±9.10)	14.27 (±8.77)	18.11 (±9.08)
Diagnosed at Birth (Congenital) (%)	NA	52.10	40.74	60.74
Positive family history (%)	NA	50.88	55.55	47.58
Parental Consanguinity (%)	NA	67.08	63.46	69.70

489 Values are N for total, percentage (%) for gender and diagnosed at birth, Mean (SD) for age, NA, not applicable.

490 *Limitation: Most of the strabismus patients were young children (below the age of 10), but we could not obtain
491 approval of guardians to sample an equal number of unaffected children, thus we used older individuals (ages >14).

492 **Supplementary Table 3:** Distribution of allele frequencies among the control and disease group along with the calculated and
 493 reported minor allele frequencies (MAFs).

RS Number	Ancestral allele (A1)	Risk allele (A2)	A1 frequency		A2 frequency		MAF ¹	MAF ²	MAF ³	χ^2 (p-value) ⁴	χ^2 (p-value) ⁵
			Control (n (%))	Disease (n (%))	Control (n (%))	Disease (n (%))					
Rs2896218	A	G	197 (44.97%)	296 (48.37%)	241 (55.02%)	316 (51.63%)	0.45(A)	0.48 (A)	0.62 (A)*	12.27 (<0.01)	8.32 (<0.01)
Rs3779550	C	T	236 (55.92%)	248 (53.45%)	186 (44.07%)	216 (46.55%)	0.44 (T)	0.46 (T)	0.32 (T)	6.62 (0.01)	9.01 (<0.01)
Rs2285544	T	A	295 (69.57%)	361 (74.27%)	129 (30.42%)	125 (25.72%)	0.30 (A)	0.26 (A)	0.39 (A)	3.41 (0.06)	7.10 (<0.01)
rs4730775	C	T	90 (71.43%)	127 (59.90%)	36 (28.57%)	85 (40.10%)	0.29 (T)	0.40 (T)	0.32 (T)	0.41 (0.52)	2.94 (0.09)
rs3840660	No ins	insA	90 (68.18%)	122 (57.55%)	42 (31.82%)	90 (42.45%)	0.32 (A)	0.42 (A)	0.34 (A)	0.18 (0.67)	2.85 (0.09)
rs2024233	A	G	66 (50.77%)	114 (54.29%)	64 (49.23%)	96 (45.71%)	0.49 (G)	0.46 (G)	0.37 (G)	6.18 (0.01)	3.48 (0.06)

494 ¹MAF calculated from control cohort of present study

495 ²MAF calculated from disease cohort

496 ³MAF reported for PjL from Ensembl (https://asia.ensembl.org/Homo_sapiens/Info/Index)

497 ⁴Chi-square results for controls and reported data (PjL from Ensembl)

498 ⁵Chi-square results for disease and reported data (PjL from Ensembl)

499 * The frequency of A allele was calculated from MAF (G) reported inPjL for rs2896218

500 Significant p-values (<0.05) are shown in bold font

501 ins stands for insertion, insA is insertion of A nucleotide

502 n, number of alleles

503 **Supplementary Table 4:** Linkage disequilibrium matrix showing D', R², chi square and p-values for the studied variants for the
 504 control cohort. Statistically significant p-values are indicated in bold font.

	rs2896218	rs3779550	rs2285544	rs4730775	rs3840660
rs3779550	D': 0.87 R ² : 0.82 Chi-sq: 72.34 p-value: <0.01				
rs2285544	D': 0.85 R ² : 0.76 Chi-sq: 61.79 p-value: <0.01	D': 0.70 R ² : 0.66 Chi-sq: 47.26 p-value: <0.01			
rs4730775	D': 0.19 R ² : 0.13 Chi-sq: 1.69 p-value: 0.19	D': 0.11 R ² : 0.08 Chi-sq: 0.66 p-value: 0.42	D': 0.08 R ² : 0.06 Chi-sq: 0.40 p-value: 0.53		
rs3840660	D': 0.36 R ² : 0.25 Chi-sq: 6.93 p-value: <0.01	D': 0.08 R ² : 0.06 Chi-sq: 0.44 p-value: 0.51	D': 0.07 R ² : 0.05 Chi-sq: 0.28 p-value: 0.60	D': 0.85 R ² : 0.79 Chi-sq: 68.10 p-value: <0.01	
rs2024233	D': 0.24 R ² : -0.13 Chi-sq: 5.02 p-value: 0.02	D': 0.14 R ² : 0.13 Chi-sq: 1.73 p-value: 0.19	D': 0.31 R ² : 0.27 Chi-sq: 7.85 p-value: <0.01	D': 0.39 R ² : -0.24 Chi-sq: 6.02 p-value: 0.01	D': 0.59 R ² : -0.38 Chi-sq: 15.36 p-value: <0.01

505